388 Market St #1300, San Francisco, CA 94111, USA

©2018 by Cellastra Inc. Proudly created with Wix.com

NEW PRESS RELEASES

CELLASTRA INC 07/15/2019

 

Cellastra announces filing of global patent application for prevention of scars and adhesions.

​​

San Francisco, CA, July 15, 2019  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has filed a PCT patent application to expand its proprietary platform in treatment and prevention of scars and adhesions after trauma including bur injuries and surgery.

​The application, which is an extension of the US patent filed on July 17 last year, covers. composition of matter, methods of administration and use of a broad range of gene vectors and lactoferrin subpeptides targeting a broad range of cells involved in scarring and adhesions.

“I am pleased to assign global exclusive rights to these inventions to Cellastra,” said Dr. Brad Thompson, the inventor, who is Chief Technology Officer and Director on the Board of Cellastra.

Dr Thompson is Cofounder and CEO of Kickshaw Ventures, Calgary, and has been instrumental providing seed funding for the ongoing GLP manufacturing and preclinical program at Guelph University, Ontario, Canada. He has more than 30 years successful career in Biotech, including Chair CANADABiotec, Cofounder, CEO and Chair of Oncolytic Biotech, and Head Biotech Alberta Research Council. He is also a prolific inventor in viral and gene therapies and involved in several new gene therapy startup companies. He obtained his B.Sc. from Alberta University and PhD in microbiology and immunology from University of Western Ontario.

 

For more information, visit our website www.cellastra.com

Contact: Karl Mettinger

510-499-6376

Karl.Mettinger@cellastra.com

 

 

 

 

CELLASTRA INC 06/24/2019

 

Cellastra announces collaboration with leading academic laboratory in Canada for manufacturing and testing of a novel gene vector programmed for scar prevention.

Preparing for clinical study in burn injuries

San Francisco, CA, June 24, 2019  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has outsourced its preclinical program in preparation  of filing an excemption for participation in a burn injury clinical  study in Europe.

The collaboration also includes GLP manufacturing of a triple-mutant AV6 viral vector with desirable characteristics for use in many  clinical indications including scar prevention in burn injury patients.

"We are pleased to be working with Dr. Sarah Wootton, PhD.  a globally recognized viral and gene therapy expert," said Dr Brad Thompson, PhD, Chief Technology Officer and Board member of Cellastra.

 

Dr Wootton is an Associate Professor of veterinary virology at the Department of Pathophysiology, Ontario Veterinary College, Guelph University. She earned her PhD in molecular virology at Guelph University in 2002 and subsequently completed a four year post doc at Fred Hutchinson Cancer Research Center  in Seattle. She is a prolific scientist with many dozens of peer reviewed publications and has won numerous awards including City of Guelph's Top 40 under 40 award and National Sciences and Research Council (NSRC) award for seven consecutive years.

"We are particularly intrigued by the recently published results obtained with the novel AV6-2FF vector," said Dr Karl Mettinger, MD, PhD, President and CEO of Cellastra.  "The AAV6 vector has been referred to as a potential gene vector of choice for expression in skin cells and the triple -mutant gene vector was found to be superior to the natural AAV6 vector," said Dr Mettinger. The report showed that the vector was easily manufactured (in HEk293 cells) and purified (column chromatography), making it suitable for large scale production (van Lieshaut et al Molecular Therapy. Methods & Clinical Development, 2018,14;9:323-329). 

 

 Compared to the natural AV6 vector the novel vector demonstrated a rapid and potent expression (ten to hundred fold higher expression in the cell systems studied (lung and muscle), and tenfold higher resistance to pre-existing AAV antibodies. Furthermore, the expression remained robust throughout the 206 day study period.  

or more information, visit our website www.cellastra.com

Contact: Karl Mettinger

510-499-6376

Karl.Mettinger@cellastra.com

 

 

 

 

CELLASTRA INC 04/04/2019

 

Cellastra announces updates from American Burn Association's Annual Meeting in Las Vegas, April 2-5, 2019

Prof. Folke Sjoberg , Cellastra Scientific Advisory Board Member  awarded to give the Everett Idris Evans Memorial Lecture on frontiers in burn injury treatment

Cellastra prepares for  clinical study in burn injury

 

San Francisco, CA, April 5, 2019  Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company attended the 51st Annual Meeting of the American Burn Association (ABA), which was held in Las Vegas with more than 1,200 participants from US, Canada and other countries around the world.

​Folke Sjöberg, Professor of burn surgery/critical care at Linkoping University, Sweden and an internationally recognized leader in the field, was invited to give this year's award Everett Idris Evans Memorial Lecture. He is past President of the European Burns Association and gave an update on research frontiers in burn injuries from his European vantage point, He also gave an update on the program using GMP cultivated keratinocytes, which is expected to enter a clinical study during this coming year. The consortium is sponsored by a 50M SEK grant from Vinnova, the Swedish Government Innovation Agency Prof Sjöberg also disclosed the plan to expand the program to a European multicenter study.  

Cellastra participated in the meeting and met met with a number of companies active in the burn injury market and discussions are ongoing about potential collaboration with Cellastra to explore the company’s  proprietary gene vector platform for scar prevention.​ Cellastra also met with professor Fiona Woods, who gave a personal account on the invention of the RECELL system, recently approved in the US. This is a simple advice to harvest skin cells from a small unaffected skin area of the patient and to prepare a suspension of skin cells ready to be sprayed on the burn wound within 30-60 minutes. 

Cellastra is currently exploring opportunities to accelerate its gene vector program into Phase 1 and 2 studies in Sweden and Europe during the next year. "Severe scarring is the number one long term physical, psychological and social handicap in more than 70 percent of severe burn injuries. This  leads to social isolation and suffering for the patient as well as  heavy economic burden for the society.

“We are excited about the opportunity and challenge to test our CELLEXA Gene Vector, as it is designed and programmed for  production of a promising  anti-scarring peptide directly in the wound area, “said Dr Karl Mettinger, President and CEO of Cellastra. The Peptide has already been demonstrated to be safe and have potent  activity in published preclinical and clinical Phase 2 studies.  Gene therapy offers the prospect of long term production of the peptide in skin cells directly in the wound area for weeks and months after one single treatment.

  

For more information, visit our website www.cellastra.com

Contact: Karl Mettinger

510-499-6376

Karl.Mettinger@cellastra.com

 

CELLASTRA INC. 01/07/2019

 

Cellastra announces 10M USD Series A capital call to support new gene therapy program for scar prevention after surgery and burn injuries

Appoints gene therapy leadership in new management positions

  • Recently acquired novel gene therapy platform including global development and commercialization rights for scar prevention.

  • First indication will be prevention of scarring and adhesions after surgery as well as burn injuries. Other indications to follow will include scar prevention after hip and knee replacement

  • One treatment may provide scar prevention for many months.

  • Dr. Larry Couture appointed  Chair of Cellastra’ s Scientific advisory Board, Dr. .Alan J. Lewis to Executive Chairman  of the Board of Directors, and  Dr. Brad Thompson to Chief Technology Officer,


San Francisco, CA, January 7, 2019 . Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has initiated a 10M USD Series A capital call to develop gene therapy for scar prevention. The company recently acquired a novel gene therapy platform including global development and commercialization rights for scar and adhesion prevention with application in a broad range of indications including dermal scarring after surgery and burn injuries as well as scarring in the joints after hip and knee replacement.

 

“We are excited that this intellectual property for development and commercialization has been assigned to Cellastra. This puts the company at the frontier of the current gene therapy revolution. This is a first in man program using this new technology for scar prevention, a major unmet need in global health care,” says Dr. Karl Mettinger, MD, PhD, cofounder, President & CEO of Cellastra. “We also welcome the opportunity to work closely with the eminent members our Scientific Advisory board, which includes international pioneers in cell and gene therapy,” says Dr. Alan Lewis, Executive Chairman of the board of directors,

 

Dr. Larry Couture, PhD, who was appointed to Chair of the Cellastra Scientific Advisory Board, has been a pioneer in Gene therapy for 30 years and previous member of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee. Dr. Couture was a key participant in numerous first-in-man clinical studies, including the first human gene therapy trials, the first direct administration to humans of a genetically engineered virus, and many other cell and gene therapy firsts. During his 20 years as Founding Director and Senior Vice President at the Center of Technology, City of Hope Dr. Couture directed the successful production of over 300 lots of clinical grade viral vectors for gene therapy, and other biological products.

 

Dr. Brad Thompson, who joined the Cellastra board two years ago, was appointed Chief technology Officer (CTO) on the Executive Team with responsibilities overseeing Cellastra’ s collaboration with Guelph University, Ontario, Canada, where contract gene therapy vector manufacturing and research are being established. He is also the inventor of several viral and gene therapy patents, including the technology platform now assigned to Cellastra. Dr. Thompson, who is the CEO and Co-Founder of Kickshaw Ventures, is an experienced and highly respected biotechnology professional for more than 30 years. Most recently he served as Director and the Chairman of BIOTECanada. He started his career in biotech as Head of Biotechnology at The Alberta Research Council where he was responsible for GMP manufacturing for biologics.

 

“Cellastra’ s gene therapy for scar prevention involves application of pre-programmed viral vectors, which turns on the production line in cell factory in the targeted  skin cells to produce anti -scarring peptides continuously delivered to the wound area for many months. ‘Such peptides have already been tested in animals and clinical studies and found to be safe and effective in studies until date, which we believe will help accelerate the development and approval of our future products,” says Dr. Mettinger.

 

For more information, visit our website www.cellastra.com

Contact: Karl Mettinger

510-499-6376

Karl.Mettinger@cellastra.com

 

CELLASTRA INC. 12/01/2018

 

Cellastra announces the appointment accounting veteran Bruce Phillips as new Chief Financial Officer.  

 

San Francisco, CA, , December 1, 2018, Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has appointed Bruce Phillips, CPA, as new Chief Financial Officer.

 

Bruce Phillips has a long and distinguished career in the accounting industry for more than 3o years. After graduating from the College of William & Mary he joined Arthur Young and became an accounting manager for Ernst & Young. In 1992, he became a Founding Partner, and later CEO of HPC (Harshman, Phillips & Company) which for decades operated as a traditional accounting firm in Atlanta. At the annual accounting convention In 2011 he met Rodney Drury, the founder of XERO, the pioneer of the cloud based accounting technology platform, Soon HPC became a Platinum Partner of XERO and leading cloud based accounting firm and is today a full service provider working remotely all over United States, from California, to Florida and New Hampshire and with an increasing number of clients all over the globe. 

“We are excited that this appointment happens at this junction as we recently acquired a proprietary platform for anti scarring gene therapy. This puts the company at the frontier of the current gene therapy revolution. This is a first in man program using this new technology for scar prevention, a major unmet need in global health care,” says Dr. Karl Mettinger, MD, PhD, cofounder, President & CEO of Cellastra.

 

For more information, visit our website www.cellastra.com

Contact: Karl Mettinger

510-499-6376

Karl.Mettinger@cellastra.com

CELLASTRA INC. 11/01/2018

 

Cellastra announces acquisition of a novel gene therapy platform including global development and commercialization rights for scar prevention

 

  • First indication will be prevention of scarring and adhesions after surgery as well as burn injuries. Other indications to follow will include scar prevention after hip and knee replacement

  • One treatment may provide scar prevention for many months.


San Francisco, CA, November 1, 2018, Cellastra, Inc., a developer of novel cell and gene therapy assets, announced today that the company has acquired intellectual property platform for gene therapy for scar prevention. The acquisition includes global development and commercialization rights for scar and adhesion prevention with application in a broad range of indications including dermal scarring after surgery and burn injuries as well as scarring in the joints after hip and knee replacement.

 

“We are excited that this intellectual property for development and commercialization has been assigned to Cellastra. This puts the company at the frontier of the current gene therapy revolution. This is a first in man program using this new technology for scar prevention, a major unmet need in global health care,” says Dr. Karl Mettinger, MD, PhD, cofounder, President & CEO of Cellastra.

Dr. Brad Thompson, who joined the Cellastra board two years ago, is also the inventor of several viral and gene therapy patents, including the technology platform now assigned to Cellastra. Dr. Thompson, who is the CEO and Co-Founder of Kickshaw Ventures, is an experienced and highly respected biotechnology professional for more than 30 years. Most recently he served as Director and the Chairman of BIOTECanada. He started his career in biotech as Head of Biotechnology at The Alberta Research Council where he was responsible for GMP manufacturing for biologics.

 

The intellectual property acquired relates to a recent patent filing “Methods for regulating endogenous production of lactoferrin and sub-peptides thereof and covers a broad range of viral vectors, routes of administration and therapeutic indications.

 

“Cellastra’ s gene therapy for scar prevention involves application of pre-programmed viral vectors, which turns on the production line in cell factory in the targeted  skin cells to produce anti -scarring peptides continuously delivered to the wound area for many months. ‘Such peptides have already been tested in animals and clinical studies and found to be safe and effective in studies until date, which we believe will help accelerate the development and approval of our future products,” says Dr. Mettinger.

 

For more information, visit our website www.cellastra.com

Contact: Karl Mettinger

510-499-6376

Karl.Mettinger@cellastra.com